Recent Updates
Recently added Catalysts
LXRX Positive Sentiment

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

Key Takeaway: Lexicon Pharmaceuticals announced it will release its fourth quarter 2025 financial results on March 5, 2026. The company will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Participants can access the call via webcast and will have the opportunity to ask questions.
Price reaction · baseline $1.5 (2026-02-25 close) · hit pre-market · clean, no other LXRX news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Lexicon Pharmaceuticals is actively engaging with investors.
  • The company has a diverse pipeline of drug candidates.
  • The upcoming financial results may indicate positive growth.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus

Full Press Release Details

THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Participants can access the conference call live via webcast on the Events page of the Company’s website athttps://investors.lexpharma.com/. Participants who wish to ask a question mayregister hereto receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.
About Lexicon PharmaceuticalsLexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications.

For Investor and Media Inquiries:Lisa DeFrancescoLexicon Pharmaceuticals, Inc.lexinvest@lexpharma.com

Frequently Asked Questions

When will Lexicon Pharmaceuticals report its Q4 2025 results?

Lexicon Pharmaceuticals will report its Q4 2025 financial results on March 5, 2026.

What time is the conference call for Q4 results?

The conference call will take place at 8:30 a.m. ET on March 5, 2026.

How can I access the conference call?

Participants can access the conference call live via webcast on the company's Events page.

What topics will be discussed in the conference call?

The call will discuss the financial results and provide a business update.

Last updated: Feb 26, 2026